📊 IBRX Key Takeaways
Is ImmunityBio, Inc. (IBRX) a Good Investment?
ImmunityBio exhibits severe financial distress with negative stockholders' equity of -$870M, catastrophic net losses of -$632.8M against minimal $44.2M revenue, and negative free cash flow of -$77.1M that will deplete cash reserves within 3 years. The company demonstrates no revenue growth momentum and profitability metrics so negative that fundamental business model viability is in question.
Fundamentals are severely strained: the company posts deep operating and net losses with extremely negative margins, flat revenue growth, and negative stockholders’ equity. Cash burn far exceeds cash on hand and interest coverage is negative, indicating reliance on external financing to continue operations. While short‑term liquidity ratios are strong, long‑term solvency and path to sustainable profitability are highly uncertain.
Why Buy ImmunityBio, Inc. Stock? IBRX Key Strengths
- $205.2M cash balance provides near-term liquidity buffer for operations
- Current ratio of 6.67x indicates adequate short-term liquidity to meet immediate obligations
- EPS improved 38.7% YoY showing reduction in loss magnitude per share
- Strong current and quick ratios indicating short-term liquidity
- Low capex intensity relative to operating scale
- Established (though flat) revenue base of ~$113M
IBRX Stock Risks: ImmunityBio, Inc. Investment Risks
- Negative stockholders' equity of -$870M indicates technical insolvency and material bankruptcy risk
- Negative free cash flow of -$77.1M at current burn rate exhausts cash in <3 years without profitability inflection
- Zero revenue growth with operating losses of -$69.8M reveals fundamental business model dysfunction
- Net margin of -1431.4% suggests unsustainable cost structure relative to revenue base
- Likely need for dilutive equity raises as cash burns, creating shareholder dilution risk
- Negative stockholders’ equity and potential solvency/going‑concern risk
- Heavy operating cash burn necessitating external financing and dilution
- Persistently negative operating and net margins with no revenue growth
Key Metrics to Watch
- Quarterly operating cash flow trend and cash runway calculation
- Revenue growth rate and major product pipeline approval timeline
- Operating expense trajectory and path to gross margin expansion
- Debt refinancing needs and covenant compliance status
- Capital raise announcements and terms of dilution to existing shareholders
- Operating cash flow (burn rate)
- Revenue growth (YoY)
ImmunityBio, Inc. (IBRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.67x current ratio provides a solid financial cushion.
IBRX Profit Margin, ROE & Profitability Analysis
IBRX vs Healthcare Sector: How ImmunityBio, Inc. Compares
How ImmunityBio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ImmunityBio, Inc. Stock Overvalued? IBRX Valuation Analysis 2026
Based on fundamental analysis, ImmunityBio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ImmunityBio, Inc. Balance Sheet: IBRX Debt, Cash & Liquidity
IBRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ImmunityBio, Inc.'s revenue has grown significantly by 668% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.15 indicates the company is currently unprofitable.
IBRX Revenue Growth, EPS Growth & YoY Performance
IBRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $16.5M | -$129.6M | $-0.15 |
| Q3 2025 | $6.1M | -$67.3M | $-0.07 |
| Q2 2025 | $1.0M | -$92.6M | $-0.10 |
| Q1 2025 | $40.0K | -$129.6M | $-0.15 |
| Q3 2024 | $82.0K | -$85.7M | $-0.14 |
| Q2 2024 | $41.0K | -$134.6M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ImmunityBio, Inc. Dividends, Buybacks & Capital Allocation
IBRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ImmunityBio, Inc. (CIK: 0001326110)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IBRX
What is the AI rating for IBRX?
ImmunityBio, Inc. (IBRX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IBRX's key strengths?
Claude: $205.2M cash balance provides near-term liquidity buffer for operations. Current ratio of 6.67x indicates adequate short-term liquidity to meet immediate obligations. ChatGPT: Strong current and quick ratios indicating short-term liquidity. Low capex intensity relative to operating scale.
What are the risks of investing in IBRX?
Claude: Negative stockholders' equity of -$870M indicates technical insolvency and material bankruptcy risk. Negative free cash flow of -$77.1M at current burn rate exhausts cash in <3 years without profitability inflection. ChatGPT: Negative stockholders’ equity and potential solvency/going‑concern risk. Heavy operating cash burn necessitating external financing and dilution.
What is IBRX's revenue and growth?
ImmunityBio, Inc. reported revenue of $44.2M.
Does IBRX pay dividends?
ImmunityBio, Inc. does not currently pay dividends.
Where can I find IBRX SEC filings?
Official SEC filings for ImmunityBio, Inc. (CIK: 0001326110) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IBRX's EPS?
ImmunityBio, Inc. has a diluted EPS of $-0.62.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IBRX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, ImmunityBio, Inc. has a STRONG SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IBRX stock overvalued or undervalued?
Valuation metrics for IBRX: ROE of N/A (sector avg: 15%), net margin of -1,431.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IBRX stock in 2026?
Our dual AI analysis gives ImmunityBio, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IBRX's free cash flow?
ImmunityBio, Inc.'s operating cash flow is $-75.4M, with capital expenditures of $1.8M. FCF margin is -174.5%.
How does IBRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,431.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 6.67 (avg: 2).